Publication | Closed Access
ESPAC-3(v2): A multicenter, international, open-label, randomized controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
73
Citations
0
References
2009
Year
Surgical OncologyCancer ManagementPathologyMay 30OncologyPancreatic CancerGastrointestinal OncologyPhase Iii TrialCancer Cell BiologyClinical OncologyAdjuvant 5-Fluorouracil/folinic AcidRadiation OncologyMolecular OncologyCancer ResearchFinal TextCancer TreatmentMalignant DiseaseVersus GemcitabineTumoral PathologyMedicine
LBA4505 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]